Presentation is loading. Please wait.

Presentation is loading. Please wait.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Published byRandell Gaines Modified over 6 years ago

Similar presentations

Presentation on theme: "Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated."— Presentation transcript:

1 Disease activity over time in autoantibody-positive patients treated with belimumab.
Disease activity over time in autoantibody-positive patients treated with belimumab. (A) Systemic Lupus Erythematosus (SLE) Responder Index response rate; (B) annual frequency of flares measured by modified SLE Flare Index (mild-moderate and/or severe); (C) annual frequency of 1 new British Isles Lupus Assessment Group (BILAG) A or 2 new B scores; (D) mean percentage change in Physician’s Global Assessment (PGA) from baseline. *Includes patients originally randomized to belimumab or to placebo and switched to belimumab; patients randomized to placebo are included from first belimumab exposure; data through Year 2 include patients originally randomized to placebo or belimumab 1 or 4 mg/kg who were switched to 10 mg/kg at Week 56. †No. patients with assessments in interval. Ellen M. Ginzler et al. J Rheumatol 2014;41: ©2014 by The Journal of Rheumatology

Download ppt "Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated."

Similar presentations

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.

Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).
Effects of MMF treatment in patients with SLE

Effects of MMF treatment in patients with SLE
Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 4 Antinuclear antibodies and disease activity in SLE
Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Figure 3 Nucleic acid sensors in SLE

Figure 3 Nucleic acid sensors in SLE
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Primary care physicians visited chiefly by black patients were more likely to report they were unable to provide high-quality care to all their patients.

Primary care physicians visited chiefly by black patients were more likely to report they were unable to provide high-quality care to all their patients.
Patient disposition during open-label longterm exposure period.

Patient disposition during open-label longterm exposure period.
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Percentage of patients achieving DAS28 (CRP) < 3

Percentage of patients achieving DAS28 (CRP) < 3
Management of Systematic Lupus Erythematosus

Management of Systematic Lupus Erythematosus
Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.
Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Similar presentations

Ads by Google